16274-11-6

Basic information

• Product Name: KAEMPFEROLTETRAACETATE
• Synonyms: 2-(4-Acetoxyphenyl)-4-oxo-4H-chroMene-3,5,7-triyl triacetate;KAEMPFEROLTETRAACETATE
• CAS NO: 16274-11-6
• Molecular Formula: C₂₃H₁₈O₁₀
• Molecular Weight: 454.38302
• Mol File: 16274-11-6.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: KAEMPFEROLTETRAACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: KAEMPFEROLTETRAACETATE(16274-11-6)
• EPA Substance Registry System: KAEMPFEROLTETRAACETATE(16274-11-6)

Safety Data

• Hazardous Substances Data: 16274-11-6(Hazardous Substances Data)

Usage

General Description

Kaempferol tetraacetate is a chemical compound derived from kaempferol, a flavonoid found in various plants such as tea, broccoli, and onions. It belongs to the class of polyphenolic compounds and exhibits antioxidant, anti-inflammatory, and anticancer properties. Kaempferol tetraacetate has been studied for its potential as a therapeutic agent for various diseases, including cancer, diabetes, and cardiovascular disorders. It has also shown promising results in protecting cells from oxidative stress and inflammation. Further research is ongoing to explore its medicinal potential and safety profile for potential use in pharmaceutical and healthcare applications.

Upstream product

• 520-18-3 kaempferol 
• 108-24-7 acetic anhydride 
• 127-09-3 sodium acetate 

Downstream Products

• 1592-70-7 3-methoxy-5,7,4'-trihydroxyflavone 
• 33554-54-0 3,7-dihydroxy-5,4'-dimethoxyflavone 
• 491-54-3 4'-O-methylkaempferol 
• 1570-12-3 7-O-benzyl-3,4′-di-O-methylkaempferol 
• 20869-95-8 ermanin 
• 13323-01-8 7-O-methyl-3,4',5-tri-O-acetylkaempferol 
• 569-92-6 rhamnocitrin 
• 15486-33-6 4',7,-di-O-methylkaempferol 

Relevant articles and documents

Polymethoxyflavones from Gardenia oudiepe (Rubiaceae) induce cytoskeleton disruption-mediated apoptosis and sensitize BRAF-mutated melanoma cells to chemotherapy

A series of 10 natural and semisynthetic flavonoids (1 to 10) were obtained from Gardenia oudiepe (Rubiaceae), an endemic plant from New Caledonia. Most of them were polymethoxylated flavones (PMFs) of rare occurrence. After a cell viability screening test, PMFs 2 and 3 showed significant cytotoxic activity against A2058 human melanoma cells (IC50 = 3.92 and 8.18 μM, respectively) and were selected for in-depth pharmacological assays. Both compounds inhibited cell migration and induced apoptosis and cell cycle arrest after 72h of treatment. Immunofluorescence assays indicated that these outcomes were possibly related to the induction of cytoskeleton disruption associated to actin and tubulin depolymerization. These data were confirmed by molecular docking studies, which showed a good interaction between PMFs 2 and 3 and tubulin, particularly at the colchicine binding site. As A2058 are considered as chemoresistant to conventional chemotherapy, compounds 2 and 3 (?IC50) were associated to clinically-used antimelanoma drugs (vemurafenib and dacarbazine) and combined therapies efficacy was assessed by the MTT assay. PMFs 2 restored the sensitivity of A2058 cells to dacarbazine treatment (IC50 = 49.38 μM vs. >100 μM). Taken together, these data suggest that PMFs from G. oudiepe could be potential leaders for the design of new antimelanoma drugs.

ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS

Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.